Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Riedl

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|February 15, 2015
Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacksH Henry Li, Dumitru Moldovan, Jonathan A Bernstein, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 23, 2015
Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacksTimothy J Craig, H Henry Li, Marc Riedl, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 4, 2013
Analysis of hereditary angioedema attacks requiring a second dose of ecallantideH Henry Li, Marilyn Campion, Timothy J Craig, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|December 12, 2023
Patient outcomes associated with subcutaneous C1INH prophylaxis for hereditary angioedema: a retrospective analysisWilliam Lumry, Timothy Craig, John Anderson, et al.
Allergy and Asthma Proceedings|February 12, 2013
Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panelBruce L Zuraw, Konrad Bork, Karen E Binkley, et al.
Pediatrics|December 13, 2016
Management of Children With Hereditary Angioedema Due to C1 Inhibitor DeficiencyMichael M Frank, Bruce Zuraw, Aleena Banerji, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 30, 2011
Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trialWilliam R Lumry, H Henry Li, Robyn J Levy, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 26, 2014
US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiencyBruce L Zuraw, Aleena Banerji, Jonathan A Bernstein, et al.
Allergy and Asthma Proceedings|May 16, 2015
Current state of hereditary angioedema management: a patient surveyAleena Banerji, Paula Busse, Sandra C Christiansen, et al.
Allergy and Asthma Proceedings|March 15, 2013
Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation studyWilliam R Lumry, Jonathan A Bernstein, H Henry Li, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
The Journal of Allergy and Clinical Immunology. in Practice|February 15, 2015
Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacksH Henry Li, Dumitru Moldovan, Jonathan A Bernstein, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 23, 2015
Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacksTimothy J Craig, H Henry Li, Marc Riedl, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 4, 2013
Analysis of hereditary angioedema attacks requiring a second dose of ecallantideH Henry Li, Marilyn Campion, Timothy J Craig, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|December 12, 2023
Patient outcomes associated with subcutaneous C1INH prophylaxis for hereditary angioedema: a retrospective analysisWilliam Lumry, Timothy Craig, John Anderson, et al.
Allergy and Asthma Proceedings|February 12, 2013
Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panelBruce L Zuraw, Konrad Bork, Karen E Binkley, et al.
Pediatrics|December 13, 2016
Management of Children With Hereditary Angioedema Due to C1 Inhibitor DeficiencyMichael M Frank, Bruce Zuraw, Aleena Banerji, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 30, 2011
Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trialWilliam R Lumry, H Henry Li, Robyn J Levy, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 26, 2014
US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiencyBruce L Zuraw, Aleena Banerji, Jonathan A Bernstein, et al.
Allergy and Asthma Proceedings|May 16, 2015
Current state of hereditary angioedema management: a patient surveyAleena Banerji, Paula Busse, Sandra C Christiansen, et al.
Allergy and Asthma Proceedings|March 15, 2013
Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation studyWilliam R Lumry, Jonathan A Bernstein, H Henry Li, et al.
Pageof 5